Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Transitional cell carcinoma
ADR ID BADD_A04374
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.08      Renal and urinary tract neoplasms malignant and unspecified
16.08.04      Urinary tract neoplasms malignant NEC
16.08.04.002      Transitional cell carcinoma
20      Renal and urinary disorders
20.08      Genitourinary tract disorders NEC
20.08.01      Genital and urinary tract disorders NEC
20.08.01.010      Transitional cell carcinoma
Description A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. [MeSH]
MedDRA Code 10044412
MeSH ID D002295
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Carcinoma transitional cell | Transitional cell carcinoma | Urothelial carcinoma | Papillary urothelial carcinoma | Urothelial carcinoma non-resectable | Carcinoma, Transitional Cell | Carcinomas, Transitional Cell | Cell Carcinoma, Transitional | Cell Carcinomas, Transitional | Transitional Cell Carcinoma | Transitional Cell Carcinomas
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00151Apixaban0.000043%
BADD_D00347Candesartan cilexetil0.000841%
BADD_D00563Dabigatran0.000245%
BADD_D00680Dimethyl fumarate0.000600%
BADD_D01119Ibrutinib0.000112%
BADD_D01252Leflunomide0.001071%
BADD_D01253Lenalidomide0.000482%
BADD_D01260Leuprolide acetate0.001434%
BADD_D01322Losartan0.000025%
BADD_D01654Palbociclib0.000112%
BADD_D01777Pioglitazone0.000215%
BADD_D01783Pirfenidone0.000241%
BADD_D01913Ranitidine0.000100%
BADD_D01954Rivaroxaban0.000063%
BADD_D02236Tofacitinib0.000241%
BADD_D02342Vedolizumab--
BADD_D02464Fingolimod0.000482%
BADD_D02506Erdafitinib0.000168%
The 1th Page    1    Total 1 Pages